JPWO2020012177A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020012177A5 JPWO2020012177A5 JP2021500530A JP2021500530A JPWO2020012177A5 JP WO2020012177 A5 JPWO2020012177 A5 JP WO2020012177A5 JP 2021500530 A JP2021500530 A JP 2021500530A JP 2021500530 A JP2021500530 A JP 2021500530A JP WO2020012177 A5 JPWO2020012177 A5 JP WO2020012177A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- polypeptide
- set forth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 127
- 229920001184 polypeptide Polymers 0.000 claims description 122
- 229920000023 polynucleotide Polymers 0.000 claims description 31
- 239000002157 polynucleotide Substances 0.000 claims description 31
- 201000009910 diseases by infectious agent Diseases 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 14
- 101710026728 BU182 Proteins 0.000 claims description 8
- 101710036455 TK0537 Proteins 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 230000001684 chronic Effects 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 230000003612 virological Effects 0.000 claims description 3
- 206010001897 Alzheimer's disease Diseases 0.000 claims description 2
- 206010003246 Arthritis Diseases 0.000 claims description 2
- 206010008874 Chronic fatigue syndrome Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 206010011401 Crohn's disease Diseases 0.000 claims description 2
- 208000004232 Enteritis Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims description 2
- 210000000936 Intestines Anatomy 0.000 claims description 2
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 claims description 2
- 206010024229 Leprosy Diseases 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 2
- 206010061536 Parkinson's disease Diseases 0.000 claims description 2
- 108050006987 Poxvirus Proteins 0.000 claims description 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims description 2
- 206010043778 Thyroiditis Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 201000009794 idiopathic pulmonary fibrosis Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 201000004681 psoriasis Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 201000002661 spondylitis Diseases 0.000 claims description 2
- 230000001256 tonic Effects 0.000 claims description 2
- 201000006704 ulcerative colitis Diseases 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 3
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims 1
- 241000186367 Mycobacterium avium Species 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 229960005486 vaccines Drugs 0.000 description 32
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- -1 gsd Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
Description
キット
本発明はまた、容器中にキットの形態でパッケージ化されている、本発明の治療での使用に好適な本明細書に記載の構成成分の組合せにも関する。そのようなキットは、本発明の治療を可能にする一連の構成成分を含み得る。例えば、キットは、本発明の2つ以上の異なるベクター、又は本発明の1つ以上のベクター、並びに同時投与、又は例えばプライム及びブーストプロトコールを使用する逐次若しくは個別投与に好適な1つ以上の追加の治療剤を含み得る。キットは、場合により、他の好適な試薬(複数可)、対照(複数可)、又は説明書等を含有し得る。
本発明は以下の態様も提供する。
［1］ 対象においてMAP感染又はMAP感染に関連する状態若しくは症状を治療又は予防する方法での使用のための、配列番号2に示すMAP P900の領域由来の少なくとも9個の連続するアミノ酸のアミノ酸配列を含むポリペプチド、又は前記ポリペプチドをコードするポリヌクレオチドを含むワクチン。
［2］ ポリペプチドが、アミノ酸配列MVINDDAQRLLSQRを含む、［1］に記載の使用のためのワクチン。
［3］ ポリペプチドが、アミノ酸配列MVINDDAQRLLSQRVANDEAALLELIを含む、［2］に記載の使用のためのワクチン。
［4］ ポリペプチドが、アミノ酸配列MVINDDAQRLL[pS]QRを含む、［2］又は[3]に記載の使用のためのワクチン。
［5］ ポリペプチドが、アミノ酸配列VTTLADGGEVTWAIDを含む、［1］～[4]のいずれかに記載の使用のためのワクチン。
［6］ ポリペプチドが、アミノ酸配列VTTLADGGEVTWAIDLNAを含む、［5］に記載の使用のためのワクチン。
［7］ ポリペプチドが、アミノ酸配列EVVVAQPVWAGVDAGKADHYを含む、［１］～［6］のいずれかに記載の使用のためのワクチン。
［8］ ポリペプチドが、アミノ酸配列MTVTEVVVAQPVWAGVDAGKADHYを含む、［7］に記載の使用のためのワクチン。
［9］ 配列番号2に示すMAP P900の領域由来の少なくとも9個の連続するアミノ酸のアミノ酸配列を含む2つ以上のポリペプチド、又は前記ポリペプチドをコードする2つ以上のポリヌクレオチドを含む、［1］～[8]のいずれかに記載の使用のためのワクチン。
［10］ アミノ酸配列MVINDDAQRLLSQRを含むポリペプチド、及びアミノ酸配列MVINDDAQRLL[pS]QRを含むポリペプチドを含む、［9］に記載の使用のためのワクチン。
［11］ 以下のポリペプチド又はポリヌクレオチド：アミノ酸配列MVINDDAQRLLSQRを含むポリペプチド、又は前記ポリペプチドをコードするポリヌクレオチド、アミノ酸配列VTTLADGGEVTWAIDを含むポリペプチド、又は前記ポリペプチドをコードするポリヌクレオチド、及びアミノ酸配列EVVVAQPVWAGVDAGKADHYを含むポリペプチド、又は前記ポリペプチドをコードするポリヌクレオチドのうちの少なくとも2つを含む、［9］又は[10]に記載の使用のためのワクチン。
［12］ アミノ酸配列MVINDDAQRLLSQRVANDEAALLELIを含むポリペプチド、アミノ酸配列VTTLADGGEVTWAIDLNAを含むポリペプチド、及び/又はアミノ酸配列MTVTEVVVAQPVWAGVDAGKADHYを含むポリペプチドを含む、［11］に記載の使用のためのワクチン。
［13］ ポリペプチドが、アミノ酸配列:
(i)MVINDDAQRLLSQRX
2
VTTLADGGEVTWAID、
(ii)MVINDDAQRLLSQRX
2
VTTLADGGEVTWAIDLNA、
(iii)MVINDDAQRLLSQRVANDEAALLELIX
2
VTTLADGGEVTWAID、
(iii)MVINDDAQRLLSQRVANDEAALLELIX
2
VTTLADGGEVTWAIDLNA、
(iv)EVVVAQPVWAGVDAGKADHYX
1
MVINDDAQRLLSQR、
(vi)EVVVAQPVWAGVDAGKADHYX
1
MVINDDAQRLLSQRVANDEAALLELI、
(vii)MTVTEVVVAQPVWAGVDAGKADHYX
1
MVINDDAQRLLSQR、
(viii)MTVTEVVVAQPVWAGVDAGKADHYX
1
MVINDDAQRLLSQRVANDEAALLELI、
(ix)MVINDDAQRLLSQRVDAGKADHYAVTTLADGGEVTWAID、
(x)MVINDDAQRLLSQRVDAGKADHYAVTTLADGGEVTWAIDLNA、
(xi)MVINDDAQRLLSQRVDAGKADHYAVTTLADGGEVTWAIDLNAGGAALLIALLIAAGQRLLYIPGX
3
TVHHAAGSYRGE、又は
(xii)MTVTEVVVAQPVWAGVDAGKADHYCMVINDDAQRLLSQRVANDEAALLELIAAVTTLADGGEVTWAIDLNAGGAALLIALLIAAGQRLLYIPGX
3
TVHHAAGSYRGE
[式中、X
1
はペプチドリンカー又はCであり、X
2
はペプチドリンカー、A又はAAであり、X
3
はR又はAである]
を含む、［1］～[12]のいずれかに記載の使用のためのワクチン。
［14］ ポリペプチドが、アミノ酸配列
(i)EVVVAQPVWAGVDAGKADHYX
1
MVINDDAQRLLSQRVANDEAALLELI X
2
VTTLADGGEVTWAIDLNA、又は
(ii)MTVTEVVVAQPVWAGVDAGKADHYX
1
MVINDDAQRLLSQRVANDEAALLELI X
2
VTTLADGGEVTWAIDLNA
[式中、X
1
はペプチドリンカー又はCであり、X
2
はペプチドリンカー、A又はAAである]
を含む、［13］に記載の使用のためのワクチン。
［15］ ポリペプチドが少なくとも1つの追加のMAPポリペプチド、又はその断片のアミノ酸配列をさらに含む、［1］～[14]のいずれかに記載の使用のためのワクチン。
［16］ 少なくとも1つの追加のMAPポリペプチド若しくはその断片のアミノ酸配列を含むポリペプチド、又は追加のMAPポリペプチド若しくはその断片をコードする少なくとも1つのさらなるポリヌクレオチドをさらに含む、［1］～[15]のいずれかに記載の使用のためのワクチン。
［17］ 追加のMAPポリペプチドが、ahpCポリペプチド、gsdポリペプチド、p12ポリペプチド、及びmpaポリペプチドのうちの少なくとも1つである、［15］又は[16]に記載の使用のためのワクチン。
［18] (a)ahpCポリペプチドが、配列番号22の配列、配列番号22の全長にわたって配列番号22と70%を超えるアミノ酸配列同一性を有するその変異体、又はエピトープを含む配列番号22の少なくとも8個のアミノ酸の断片を含み、
(b)gsdポリペプチドが、配列番号24の配列、配列番号24の全長にわたって配列番号24と70%を超えるアミノ酸配列同一性を有するその変異体、又はエピトープを含む配列番号24の少なくとも8個のアミノ酸の断片を含み、
(c)p12ポリペプチドが、配列番号26の配列、配列番号26の全長にわたって配列番号26と70%を超えるアミノ酸配列同一性を有するその変異体、又はエピトープを含む配列番号26の少なくとも8個のアミノ酸の断片を含み、及び/又は
(d)mpaポリペプチドが、配列番号30の配列、配列番号30の全長にわたって配列番号30と70%を超えるアミノ酸配列同一性を有するその変異体、又はエピトープを含む配列番号30の少なくとも8個のアミノ酸の断片を含む、
［17］に記載の使用のためのワクチン。
［19］ (a)前記ahpCポリペプチドが、配列番号32に示すアミノ酸配列を有し、及び/又は、
(b)前記gsdポリペプチドが、配列番号34に示すアミノ酸配列を有し、及び/又は、
(c)前記p12ポリペプチドが、配列番号36若しくは配列番号38に示すアミノ酸配列を有し、及び/又は、
(d)前記mpaポリペプチドが、配列番号40に示すアミノ酸配列を有する、
［17］又は[18]に記載の使用のためのワクチン。
［20］ ポリペプチドが、配列番号41に示すアミノ酸配列であって、但しアミノ酸配列MVINDDAQRLLSQRを含むペプチドがN末端に付加されている、若しくは7位と8位、199位と200位、442位と443位、577位と578位、及び/若しくは820位と821位の間に挿入されている、アミノ酸配列、又は配列番号42に示すアミノ酸配列であって、但しアミノ酸配列MVINDDAQRLLSQRを含むペプチドがN末端に付加されている、若しくは7位と8位、199位と200位、442位と443位、582位と583位、及び/若しくは825位と826位の間に挿入されている、アミノ酸配列を含む、［17］～[19]のいずれかに記載の使用のためのワクチン。
［21］ ポリペプチドが、配列番号62、63、64、65、66、67、68及び69のいずれか1つに示すアミノ酸配列を含む、［20］に記載の使用のためのワクチン。
［22］ ポリヌクレオチドが、前記ポリペプチド、又は前記ポリペプチドのうちの少なくとも1つをコードするヌクレオチド配列の2つ以上のコピーを含む、［1］～[21]のいずれかに記載の使用のためのワクチン。
［23］ MAP感染に関連する状態又は症状が、腸の慢性炎症、クローン病、ヨーネ病、潰瘍性大腸炎、乾癬、甲状腺炎、サルコイドーシス、パーキンソン病、多発性硬化症、1型糖尿病、関節炎、強直性脊椎炎、関節リウマチ、過敏性腸症候群、炎症性腸疾患、慢性腸炎、アルツハイマー病、多発性硬化症、突発性肺繊維症、らい病及び/又は慢性疲労性症候群である、［1］～[22]のいずれかに記載の使用のためのワクチン。
［24］ 対象が、ヒト、家畜動物、実験動物、又は飼育動物である、［1］～[23]のいずれかに記載の使用のためのワクチン。
［25］ 方法が、MAPに対する活性を有するさらなる治療剤又はMAP感染に関連する状態の治療で使用されるさらなる治療剤を対象に投与するステップを含む、［1］～[24]のいずれかに記載の使用のためのワクチン。
［26］ アミノ酸配列:MVINDDAQRLLSQRVANDEAALLELIを含む、最大100アミノ酸のペプチド。
［27］ アミノ酸配列:
(i)VTTLADGGEVTWAID若しくはVTTLADGGEVTWAIDLNA、及び/又は
(ii)EVVVAQPVWAGVDAGKADHY若しくはMTVTEVVVAQPVWAGVDAGKADHY
をさらに含む、［25］に記載のペプチド。
［28］ アミノ酸配列:
(i)MVINDDAQRLLSQRX
2
VTTLADGGEVTWAID、
(ii)MVINDDAQRLLSQRX
2
VTTLADGGEVTWAIDLNA、
(iii)MVINDDAQRLLSQRVANDEAALLELIX
2
VTTLADGGEVTWAID、
(iv)MVINDDAQRLLSQRVANDEAALLELIX
2
VTTLADGGEVTWAIDLNA、
(v)EVVVAQPVWAGVDAGKADHYX
1
MVINDDAQRLLSQR、
(vi)EVVVAQPVWAGVDAGKADHYX
1
MVINDDAQRLLSQRVANDEAALLELI、
(vii)MTVTEVVVAQPVWAGVDAGKADHYX
1
MVINDDAQRLLSQR、
(viii)MTVTEVVVAQPVWAGVDAGKADHYX
1
MVINDDAQRLLSQRVANDEAALLELI、
(ix)EVVVAQPVWAGVDAGKADHYX
1
MVINDDAQRLLSQRVANDEAALLELIX
2
VTTLADGGEVTWAIDLNA、又は
(x)MTVTEVVVAQPVWAGVDAGKADHYX
1
MVINDDAQRLLSQRVANDEAALLELIX
2
VTTLADGGEVTWAIDLNA、
(xi)MVINDDAQRLLSQRVDAGKADHYAVTTLADGGEVTWAID;
(xii)MVINDDAQRLLSQRVDAGKADHYAVTTLADGGEVTWAIDLNA、
(xiii)MVINDDAQRLLSQRVDAGKADHYAVTTLADGGEVTWAIDLNAGGAALLIALLIAAGQRLLYIPGX
3
TVHHAAGSYRGE、又は
(xiv)MTVTEVVVAQPVWAGVDAGKADHYCMVINDDAQRLLSQRVANDEAALLELIAAVTTLADGGEVTWAIDLNAGGAALLIALLIAAGQRLLYIPGX
3
TVHHAAGSYRGE
[式中X
1
はペプチドリンカー又はCであり、X
2
はペプチドリンカー、A又はAAであり、X
3
はA又はRである]
を含む、［26］又は[27]に記載のペプチド。
［29］ アミノ酸配列MVINDDAQRLL[pS]QRVANDEAALLELIを含む、［26］～[28]のいずれかに記載のペプチド。
［30］ アミノ酸配列MVINDDAQRLLSQR、並びにahpCポリペプチド、gsdポリペプチド、p12ポリペプチド、及び/又はmpaポリペプチドを含む、ポリペプチド。
［31］ アミノ酸配列MVINDDAQRLL[pS]QRを含む、［30］に記載のポリペプチド。
［32］ (a)前記ahpCポリペプチドが、配列番号32に示すアミノ酸配列を有する、及び/又は
(b)前記gsdポリペプチドが、配列番号34に示すアミノ酸配列をする、及び/又は
(c)前記p12ポリペプチドが、配列番号36に示すアミノ酸配列を有する、及び/又は
(d)前記mpaポリペプチドが、配列番号40に示すアミノ酸配列を有する、
［30］又は[31]に記載のポリペプチド。
［33］ 配列番号41に示すアミノ酸配列であって、但しアミノ酸配列MVINDDAQRLLSQRを含むペプチドがN末端に付加されている、若しくは7位と8位、199位と200位、442位と443位、577位と578位、及び/若しくは820位と821位の間に挿入されている、アミノ酸配列、又は配列番号42に示すアミノ酸配列であって、但しアミノ酸配列MVINDDAQRLLSQRを含むペプチドがN末端に付加されている、若しくは7位と8位、199位と200位、442位と443位、582位と583位、及び/若しくは825位と826位の間に挿入されている、アミノ酸配列を含む、［30］～[32]のいずれかに記載のポリペプチド。
［34］ 配列番号62、63、64、65、67、68及び69のいずれか1つに示すアミノ酸配列を含む、［33］に記載のポリペプチド。
［35］ アミノ酸配列MVINDDAQRLLSQRを含むペプチドが、［26］～[29]のいずれかに記載のペプチドである、［30］～[32]のいずれかに記載のポリペプチド。
［36］ ［26］～[29]のいずれかに記載のペプチド又は［30］～[35]のいずれかに記載のポリペプチドをコードするポリヌクレオチド。
［37］ 配列番号2に示すMAP P900の領域由来の少なくとも9個の連続するアミノ酸のアミノ酸配列を含むポリペプチドをコードするポリヌクレオチドを含むワクチンベクター。
［38］ ポリヌクレオチドが、アミノ酸配列MVINDDAQRLLSQRを含むポリペプチドをコードする、又は［36］に記載のポリヌクレオチドである、［37］に記載のワクチンベクター。
［39］ ベクターが、ウイルスベクターである、［38］に記載のワクチンベクター。
［40］ ウイルスベクターが、アデノウイルスベクター又はポックスウイルスベクターである、［39］に記載のワクチンベクター。
［41］ 対象における、MAP感染又はMAP感染に関連する状態若しくは症状を治療又は予防する方法での使用のための、アミノ酸配列MVINDDAQRLLSQRからなるペプチド、［26］～[29]のいずれかに記載のペプチド、［30］～[35]のいずれかに記載のポリペプチド、［36］に記載のポリヌクレオチド、又は［37］～[40]のいずれかに記載のワクチンベクター。
［42］ MAP感染又はMAP感染に関連する状態若しくは症状を治療又は予防する方法であって、有効量の、配列番号2に示すMAP P900の領域由来の少なくとも9個の連続するアミノ酸のアミノ酸配列を含むポリペプチド、若しくは前記ポリペプチドをコードするポリヌクレオチド、アミノ酸配列MVINDDAQRLLSQRからなるペプチド、［26］～[29]のいずれかに記載のペプチド、［30］～[35]のいずれかに記載のポリペプチド、［36］に記載のポリヌクレオチド、又は［37］～[40]のいずれかに記載のワクチンベクターを、それを必要とする対象に投与するステップを含む方法。
［43］ MAP感染又はMAP感染に関連する状態若しくは症状を治療又は予防することにおける使用のためのキットであって、(i)配列番号2に示すMAP P900の領域由来の少なくとも9個の連続するアミノ酸のアミノ酸配列を含むポリペプチド、若しくは前記ポリペプチドをコードするポリヌクレオチド、アミノ酸配列MVINDDAQRLLSQRからなるペプチド、［26］～[29]のいずれかに記載のペプチド、［30］～[35]のいずれかに記載のポリペプチド、［36］に記載のポリヌクレオチド、又は［37］～[40]のいずれかに記載のワクチンベクターのうちの少なくとも1つ、及び(ii)同時、逐次、又は個別使用のための少なくとも1つの他の治療剤を含む、キット。
Kit The present invention also relates to a combination of the components described herein that are packaged in a container in the form of a kit and are suitable for use in the treatment of the present invention. Such a kit may include a set of components that enable the treatment of the present invention. For example, the kit may include two or more different vectors of the invention, or one or more vectors of the invention, and one or more additions suitable for simultaneous administration, or for sequential or individual administration using, for example, prime and boost protocols. May include therapeutic agents for. The kit may optionally contain other suitable reagents (s), controls (s), instructions, etc.
The present invention also provides the following aspects.
[1] Amino acid sequence of at least 9 contiguous amino acids from the region of MAP P900 set forth in SEQ ID NO: 2 for use in a subject with MAP infection or a condition or symptom associated with MAP infection. A vaccine comprising a polypeptide comprising, or a polynucleotide encoding the polypeptide.
[2] The vaccine for use according to [1], wherein the polypeptide comprises the amino acid sequence MVINDDAQRLLSQR.
[3] The vaccine for use according to [2], wherein the polypeptide comprises the amino acid sequence MVINDDAQRLLSQRVANDEAALLELI.
[4] The vaccine for use according to [2] or [3], wherein the polypeptide comprises the amino acid sequence MVINDDAQRLL [pS] QR.
[5] The vaccine for use according to any one of [1] to [4], wherein the polypeptide comprises the amino acid sequence VTTLADGGEVTWAID.
[6] The vaccine for use according to [5], wherein the polypeptide comprises the amino acid sequence VTTLADGGEVTWAIDLNA.
[7] The vaccine for use according to any one of [1] to [6], wherein the polypeptide comprises the amino acid sequence EVVVAQPVWAGVDAGKADHY.
[8] The vaccine for use according to [7], wherein the polypeptide comprises the amino acid sequence MTVTEVVVAQPVWAGVDAGKADHY.
[9] Containing two or more polypeptides comprising an amino acid sequence of at least nine contiguous amino acids from the region of MAP P900 set forth in SEQ ID NO: 2, or two or more polynucleotides encoding said polypeptide [9]. Vaccine for use according to any one of 1] to [8].
[10] The vaccine for use according to [9], comprising a polypeptide comprising the amino acid sequence MVINDDAQRLLSQR and a polypeptide comprising the amino acid sequence MVINDDAQRLL [pS] QR.
[11] The following polypeptides or polynucleotides: a polypeptide containing the amino acid sequence MVINDDAQRLLSQR, or a polynucleotide encoding the polypeptide, a polypeptide containing the amino acid sequence VTTLADGGEVTWAID, or a polynucleotide encoding the polypeptide, and an amino acid sequence. The vaccine for use according to [9] or [10], which comprises a polypeptide containing EVVVAQPVWAGVDAGKADHY, or at least two of the polynucleotides encoding said polypeptide.
[12] The vaccine for use according to [11], which comprises a polypeptide comprising the amino acid sequence MVINDDAQRLLSQRVANDEAALLELI, a polypeptide comprising the amino acid sequence VTTLADGGEVTWAIDLNA, and / or a polypeptide comprising the amino acid sequence MTVTEVVVAQPVWAGVDAGKADHY.
[13] The polypeptide has an amino acid sequence:
(i) MVINDDAQRLLSQRX 2 VTTLADGGEVTWAID,
(ii) MVINDDAQRLLSQRX 2 VTTLADGGEVTWAIDLNA,
(iii) MVINDDAQRLLSQRVANDEAALLELIX 2 VTTLADGGEVTWAID,
(iii) MVINDDAQRLLSQRVANDEAALLELIX 2 VTTLADGGEVTWAIDLNA,
(iv) EVVVAQPVWAGVDAGKADHYX 1 MVINDDAQRLLSQR,
(vi) EVVVAQPVWAGVDAGKADHYX 1 MVINDDAQRLLSQRVANDEAALLELI,
(vii) MTVTEVVVAQPVWAGVDAGKADHYX 1 MVINDDAQRLLSQR,
(viii) MTVTEVVVAQPVWAGVDAGKADHYX 1 MVINDDAQRLLSQRVANDEAALLELI,
(ix) MVINDDAQRLLSQRVDAGKADHYAVTTLADGGEVTWAID,
(x) MVINDDAQRLLSQRVDAGKADHYAVTTLADGGEVTWAIDLNA,
(xi) MVINDDAQRLLSQRVDAGKADHYAVTTLADGGEVTWAIDLNAGGAALLIALLIAAGQRLLYIPGX 3 TVHHAAGSYRGE, or
(xii) MTVTEVVVAQPVWAGVDAGKADHYCMVINDDAQRLLSQRVANDEAALLELIAAVTTLADGGEVTWAIDLNAGGAALLIALLIAAGQRLLYIPGX 3 TVHHAAGSYRGE
[In the formula, X 1 is a peptide linker or C, X 2 is a peptide linker, A or AA, and X 3 is R or A].
Vaccine for use according to any one of [1] to [12], including.
[14] The polypeptide has an amino acid sequence.
(i) EVVVAQPVWAGVDAGKADHYX 1 MVINDDAQRLLSQRVANDEAALLELI X 2 VTTLADGGEVTWAIDLNA, or
(ii) MTVTEVVVAQPVWAGVDAGKADHYX 1 MVINDDAQRLLSQRVANDEAALLELI X 2 VTTLADGGEVTWAIDLNA
[In the formula, X 1 is a peptide linker or C and X 2 is a peptide linker, A or AA]
Vaccines for use according to [13], including.
[15] The vaccine for use according to any of [1] to [14], wherein the polypeptide further comprises the amino acid sequence of at least one additional MAP polypeptide, or fragment thereof.
[16] A polypeptide comprising the amino acid sequence of at least one additional MAP polypeptide or fragment thereof, or further comprising at least one additional polynucleotide encoding an additional MAP polypeptide or fragment thereof, [1]-[15]. ] Vaccines for use described in any of.
[17] The vaccine for use according to [15] or [16], wherein the additional MAP polypeptide is at least one of ahpC polypeptide, gsd polypeptide, p12 polypeptide, and mpa polypeptide. ..
[18] (a) At least of SEQ ID NO: 22 containing the sequence of SEQ ID NO: 22, a variant thereof in which the ahpC polypeptide has more than 70% amino acid sequence identity with SEQ ID NO: 22 over the entire length of SEQ ID NO: 22 or an epitope. Contains 8 amino acid fragments
(b) At least eight of SEQ ID NO: 24, wherein the gsd polypeptide comprises the sequence of SEQ ID NO: 24, its variants having more than 70% amino acid sequence identity with SEQ ID NO: 24 over the entire length of SEQ ID NO: 24, or epitopes. Contains fragments of amino acids
(c) At least eight of SEQ ID NO: 26 containing the sequence of SEQ ID NO: 26, a variant thereof in which the p12 polypeptide has more than 70% amino acid sequence identity with SEQ ID NO: 26 over the entire length of SEQ ID NO: 26, or an epitope. Contains fragments of amino acids and / or
(d) At least 8 of SEQ ID NO: 30 containing the sequence of SEQ ID NO: 30, a variant thereof in which the mpa polypeptide has more than 70% amino acid sequence identity with SEQ ID NO: 30 over the entire length of SEQ ID NO: 30, or an epitope. Contains fragments of amino acids,
Vaccine for use as described in [17].
[19] (a) The ahpC polypeptide has the amino acid sequence set forth in SEQ ID NO: 32 and / or
(b) The gsd polypeptide has the amino acid sequence set forth in SEQ ID NO: 34 and / or
(c) The p12 polypeptide has the amino acid sequence set forth in SEQ ID NO: 36 or SEQ ID NO: 38 and / or
(d) The mpa polypeptide has the amino acid sequence shown in SEQ ID NO: 40.
Vaccine for use according to [17] or [18].
[20] The polypeptide has the amino acid sequence shown in SEQ ID NO: 41, except that the peptide containing the amino acid sequence MVINDDAQRLLSQR is added to the N-terminal, or at positions 7 and 8, 199 and 200, and 442. The peptide sequence shown in the amino acid sequence or SEQ ID NO: 42 inserted between positions 443, 577 and 578, and / or 820 and 821, except that the peptide containing the amino acid sequence MVINDDAQRLLSQR is N-terminal. An amino acid sequence added to or inserted between positions 7 and 8, 199 and 200, 442 and 443, 582 and 583, and / or between 825 and 826. A vaccine for use according to any of [17] to [19], including.
[21] The vaccine for use according to [20], wherein the polypeptide comprises the amino acid sequence set forth in any one of SEQ ID NOs: 62, 63, 64, 65, 66, 67, 68 and 69.
[22] The use according to any of [1] to [21], wherein the polynucleotide comprises two or more copies of the polypeptide, or a nucleotide sequence encoding at least one of the polypeptides. Vaccine for.
[23] Conditions or symptoms associated with MAP infection include chronic inflammation of the intestine, Crohn's disease, Jone's disease, ulcerative colitis, psoriasis, thyroiditis, sarcoidosis, Parkinson's disease, multiple sclerosis, type 1 diabetes, arthritis, Tonic spondylitis, rheumatoid arthritis, irritable bowel syndrome, inflammatory bowel disease, chronic enteritis, Alzheimer's disease, multiple sclerosis, idiopathic pulmonary fibrosis, leprosy and / or chronic fatigue syndrome, [1] A vaccine for use as described in any of [22].
[24] The vaccine for use according to any one of [1] to [23], wherein the subject is a human, domestic animal, laboratory animal, or domestic animal.
[25] One of [1] to [24], wherein the method comprises administering to the subject an additional therapeutic agent having activity against MAP or an additional therapeutic agent used in the treatment of a condition associated with MAP infection. Vaccine for the described use.
[26] Amino acid sequence: Peptides of up to 100 amino acids, including MVINDDAQRLLSQRVANDEAALLELI.
[27] Amino acid sequence:
(i) VTTLADGGEVTWAID or VTTLADGGEVTWAIDLNA and / or
(ii) EVVVAQPVWAGVDAGKADHY or MTVTEVVVAQPVWAGVDAGKADHY
25. The peptide according to [25].
[28] Amino acid sequence:
(i) MVINDDAQRLLSQRX 2 VTTLADGGEVTWAID,
(ii) MVINDDAQRLLSQRX 2 VTTLADGGEVTWAIDLNA,
(iii) MVINDDAQRLLSQRVANDEAALLELIX 2 VTTLADGGEVTWAID,
(iv) MVINDDAQRLLSQRVANDEAALLELIX 2 VTTLADGGEVTWAIDLNA,
(v) EVVVAQPVWAGVDAGKADHYX 1 MVINDDAQRLLSQR,
(vi) EVVVAQPVWAGVDAGKADHYX 1 MVINDDAQRLLSQRVANDEAALLELI,
(vii) MTVTEVVVAQPVWAGVDAGKADHYX 1 MVINDDAQRLLSQR,
(viii) MTVTEVVVAQPVWAGVDAGKADHYX 1 MVINDDAQRLLSQRVANDEAALLELI,
(ix) EVVVAQPVWAGVDAGKADHYX 1 MVINDDAQRLLSQRVANDEAALLELIX 2 VTTLADGGEVTWAIDLNA, or
(x) MTVTEVVVAQPVWAGVDAGKADHYX 1 MVINDDAQRLLSQRVANDEAALLELIX 2 VTTLADGGEVTWAIDLNA,
(xi) MVINDDAQRLLSQRVDAGKADHYAVTTLADGGEVTWAID;
(xii) MVINDDAQRLLSQRVDAGKADHYAVTTLADGGEVTWAIDLNA,
(xiii) MVINDDAQRLLSQRVDAGKADHYAVTTLADGGEVTWAIDLNAGGAALLIALLIAAGQRLLYIPGX 3 TVHHAAGSYRGE, or
(xiv) MTVTEVVVAQPVWAGVDAGKADHYCMVINDDAQRLLSQRVANDEAALLELIAAVTTLADGGEVTWAIDLNAGGAALLIALLIAAGQRLLYIPGX 3 TVHHAAGSYRGE
[In the formula, X 1 is a peptide linker or C, X 2 is a peptide linker, A or AA, and X 3 is A or R].
The peptide according to [26] or [27], which comprises.
[29] The peptide according to any one of [26] to [28], which comprises the amino acid sequence MVINDDAQRLL [pS] QRVANDEAALLELI.
[30] A polypeptide comprising the amino acid sequence MVINDDAQRLLSQR, as well as ahpC, gsd, p12, and / or mpa polypeptides.
[31] The polypeptide according to [30], which comprises the amino acid sequence MVINDDAQRLL [pS] QR.
[32] (a) The ahpC polypeptide has the amino acid sequence set forth in SEQ ID NO: 32 and / or
(b) The gsd polypeptide has the amino acid sequence set forth in SEQ ID NO: 34 and / or
(c) The p12 polypeptide has the amino acid sequence set forth in SEQ ID NO: 36 and / or
(d) The mpa polypeptide has the amino acid sequence shown in SEQ ID NO: 40.
The polypeptide according to [30] or [31].
[33] The amino acid sequence shown in SEQ ID NO: 41, except that the peptide containing the amino acid sequence MVINDDAQRLLSQR is added to the N-terminus, or at positions 7 and 8, 199 and 200, 442 and 443, 577. An amino acid sequence inserted between positions 578 and / or positions 820 and 821, or the amino acid sequence shown in SEQ ID NO: 42, provided with a peptide containing the amino acid sequence MVINDDAQRLLSQR added to the N-terminus. Or contains an amino acid sequence inserted between positions 7 and 8, 199 and 200, 442 and 443, 582 and 583, and / or 825 and 826, [30. ]-[32].
[34] The polypeptide according to [33], which comprises the amino acid sequence set forth in any one of SEQ ID NOs: 62, 63, 64, 65, 67, 68 and 69.
[35] The polypeptide according to any one of [30] to [32], wherein the peptide containing the amino acid sequence MVINDDAQRLLSQR is the peptide according to any one of [26] to [29].
[36] A polynucleotide encoding the peptide according to any one of [26] to [29] or the polypeptide according to any one of [30] to [35].
[37] A vaccine vector comprising a polynucleotide encoding a polypeptide comprising an amino acid sequence of at least 9 contiguous amino acids from the region of MAP P900 set forth in SEQ ID NO: 2.
[38] The vaccine vector according to [37], wherein the polynucleotide encodes a polypeptide comprising the amino acid sequence MVINDDAQRLLSQR, or is the polynucleotide according to [36].
[39] The vaccine vector according to [38], wherein the vector is a viral vector.
[40] The vaccine vector according to [39], wherein the viral vector is an adenovirus vector or a poxvirus vector.
[41] The peptide consisting of the amino acid sequence MVINDDAQRLLSQR, according to any of [26] to [29], for use in a subject in a method of treating or preventing MAP infection or a condition or symptom associated with MAP infection. The peptide, the polypeptide according to any one of [30] to [35], the polynucleotide according to [36], or the vaccine vector according to any one of [37] to [40].
[42] A method for treating or preventing a MAP infection or a condition or symptom associated with a MAP infection, wherein an effective amount of the amino acid sequence of at least 9 consecutive amino acids derived from the region of MAP P900 shown in SEQ ID NO: 2 The polypeptide contained, the polynucleotide encoding the polypeptide, the peptide consisting of the amino acid sequence MVINDDAQRLLSQR, the peptide according to any one of [26] to [29], and the poly according to any one of [30] to [35]. A method comprising the step of administering a peptide, the polynucleotide according to [36], or the vaccine vector according to any one of [37] to [40] to a subject in need thereof.
[43] A kit for use in treating or preventing MAP infections or conditions or symptoms associated with MAP infections, (i) at least 9 contiguous sequences from the region of MAP P900 set forth in SEQ ID NO: 2. A polypeptide containing an amino acid sequence of an amino acid, a polypeptide encoding the polypeptide, a peptide consisting of the amino acid sequence MVINDDAQRLLSQR, a peptide according to any one of [26] to [29], any of [30] to [35]. The polypeptide according to the above, the polypeptide according to [36], or at least one of the vaccine vectors according to any one of [37] to [40], and (ii) simultaneous, sequential, or individual use. A kit containing at least one other therapeutic agent for.
Claims (17)
(ii) 以下のポリペプチド又はポリヌクレオチド：
配列番号3に示すアミノ酸配列を含むポリペプチド若しくは前記ポリペプチドをコードするポリヌクレオチド、配列番号7に示すアミノ酸配列を含むポリペプチド若しくは前記ポリペプチドをコードするポリヌクレオチド、及び配列番号9に示すアミノ酸配列を含むポリペプチド若しくは前記ポリペプチドをコードするポリヌクレオチド
のうちの少なくとも2つ；又は
(iii) 配列番号4に示すアミノ酸配列を含むポリペプチド、配列番号8に示すアミノ酸配列を含むポリペプチド、及び/又は配列番号10に示すアミノ酸配列を含むポリペプチド
を含む、請求項3に記載の組成物。 (i) A polypeptide containing the amino acid sequence shown in SEQ ID NO: 3 and a polypeptide containing the amino acid sequence shown in SEQ ID NO: 5 ;
(ii) The following polypeptides or polynucleotides:
The polypeptide containing the amino acid sequence shown in SEQ ID NO: 3 or the polynucleotide encoding the polypeptide, the polypeptide containing the amino acid sequence shown in SEQ ID NO: 7 or the polynucleotide encoding the polypeptide, and the amino acid sequence shown in SEQ ID NO: 9. Or a polynucleotide encoding the polypeptide
At least two of; or
(iii) A polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 4, a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 8, and / or a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 10.
The composition according to claim 3 .
(ii) ポリペプチドが少なくとも1つの追加のMAPポリペプチド又はその断片のアミノ酸配列をさらに含む；又は
(iii) 組成物が少なくとも1つの追加のMAPポリペプチド若しくはその断片のアミノ酸配列を含むポリペプチド、又は追加のMAPポリペプチド若しくはその断片をコードする少なくとも1つのさらなるポリヌクレオチドをさらに含む、
請求項1～4のいずれか一項に記載の組成物。 (i) The polypeptide comprises the amino acid sequence set forth in any one of SEQ ID NOs: 11-20, 52, 58, 60, 61, 83 and 146 ;
(ii) The polypeptide further comprises the amino acid sequence of at least one additional MAP polypeptide or fragment thereof; or
(iii) The composition further comprises a polypeptide comprising an amino acid sequence of at least one additional MAP polypeptide or fragment thereof, or at least one additional polynucleotide encoding an additional MAP polypeptide or fragment thereof.
The composition according to any one of claims 1 to 4.
(a)配列番号22の配列、配列番号22の全長にわたって配列番号22と70%を超えるアミノ酸配列同一性を有するその変異体、又はエピトープを含む配列番号22の少なくとも8個のアミノ酸の断片を含むahpCポリペプチド、
(b)配列番号24の配列、配列番号24の全長にわたって配列番号24と70%を超えるアミノ酸配列同一性を有するその変異体、又はエピトープを含む配列番号24の少なくとも8個のアミノ酸の断片を含むgsdポリペプチド、
(c)配列番号26の配列、配列番号26の全長にわたって配列番号26と70%を超えるアミノ酸配列同一性を有するその変異体、又はエピトープを含む配列番号26の少なくとも8個のアミノ酸の断片を含むp12ポリペプチド、及び
(d)配列番号30の配列、配列番号30の全長にわたって配列番号30と70%を超えるアミノ酸配列同一性を有するその変異体、又はエピトープを含む配列番号30の少なくとも8個のアミノ酸の断片を含むmpaポリペプチド
のうちの少なくとも1つである、請求項5に記載の組成物。 Additional MAP polypeptides include :
(a) Containing at least eight amino acid fragments of SEQ ID NO: 22 containing the sequence of SEQ ID NO: 22, its variants having more than 70% amino acid sequence identity with SEQ ID NO: 22 over the entire length of SEQ ID NO: 22, or epitopes. ahpC polypeptide,
(b) Containing at least 8 amino acid fragments of SEQ ID NO: 24 containing the sequence of SEQ ID NO: 24, its variants having more than 70% amino acid sequence identity with SEQ ID NO: 24 over the entire length of SEQ ID NO: 24, or epitopes. gsd polypeptide,
(c) Containing at least eight amino acid fragments of SEQ ID NO: 26 containing the sequence of SEQ ID NO: 26, its variants having more than 70% amino acid sequence identity with SEQ ID NO: 26 over the entire length of SEQ ID NO: 26, or epitopes. p12 polypeptide, and
(d) Containing at least 8 amino acid fragments of SEQ ID NO: 30 containing the sequence of SEQ ID NO: 30, a variant thereof having more than 70% amino acid sequence identity with SEQ ID NO: 30 over the entire length of SEQ ID NO: 30, or an epitope. mpa polypeptide
The composition of claim 5 , which is at least one of.
前記gsdポリペプチドが、配列番号34に示すアミノ酸配列を有し、
前記p12ポリペプチドが、配列番号36若しくは配列番号38に示すアミノ酸配列を有し、及び/又は、
前記mpaポリペプチドが、配列番号40に示すアミノ酸配列を有する、
(ii) ポリペプチドが、
配列番号41に示すアミノ酸配列であって、但し配列番号3に示すアミノ酸配列を含むペプチドがN末端に付加されている、若しくは7位と8位、199位と200位、442位と443位、577位と578位、及び/若しくは820位と821位の間に挿入されている、アミノ酸配列；又は
配列番号42に示すアミノ酸配列であって、但し配列番号3に示すアミノ酸配列を含むペプチドがN末端に付加されている、若しくは7位と8位、199位と200位、442位と443位、582位と583位、及び/若しくは825位と826位の間に挿入されている、アミノ酸配列
を含む；
(iii) ポリペプチドが、配列番号62、63、64、65、66、67、68及び69のいずれか1つに示すアミノ酸配列を含む；
(iv) ポリヌクレオチドが、前記ポリペプチド、又は前記ポリペプチドのうちの少なくとも1つをコードするヌクレオチド配列の2つ以上のコピーを含む；及び／又は
(v) ポリヌクレオチドがRNA又はDNAである、
請求項6に記載の組成物。 (i) The ahpC polypeptide has the amino acid sequence set forth in SEQ ID NO: 32.
The gsd polypeptide has the amino acid sequence set forth in SEQ ID NO: 34.
The p12 polypeptide has the amino acid sequence set forth in SEQ ID NO: 36 or SEQ ID NO: 38 and / or
The mpa polypeptide has the amino acid sequence set forth in SEQ ID NO: 40.
(ii) The polypeptide is
The amino acid sequence shown in SEQ ID NO: 41, except that the peptide containing the amino acid sequence shown in SEQ ID NO: 3 is added to the N-terminal, or positions 7 and 8, 199 and 200, 442 and 443, Amino acid sequences inserted between positions 577 and 578 and / or positions 820 and 821; or
The amino acid sequence shown in SEQ ID NO: 42, except that the peptide containing the amino acid sequence shown in SEQ ID NO: 3 is added to the N-terminus, or at positions 7 and 8, 199 and 200, 442 and 443, Amino acid sequence inserted between positions 582 and 583 and / or positions 825 and 826
including;
(iii) The polypeptide comprises the amino acid sequence set forth in any one of SEQ ID NOs: 62, 63, 64, 65, 66, 67, 68 and 69;
(iv) The polynucleotide comprises two or more copies of the polypeptide, or a nucleotide sequence encoding at least one of the polypeptides; and / or
(v) The polynucleotide is RNA or DNA,
The composition according to claim 6 .
(ii) 対象が、ヒト、家畜動物、実験動物、又は飼育動物である、及び／又は
(iii) 方法が、MAPに対する活性を有するさらなる治療剤又はMAP感染に関連する状態の治療で使用されるさらなる治療剤を対象に投与するステップを含む、
請求項1～7のいずれか一項に記載の組成物。 (i) Conditions or symptoms associated with MAP infection include chronic inflammation of the intestine, Crohn's disease, Jone's disease, ulcerative colitis, psoriasis, thyroiditis, sarcoidosis, Parkinson's disease, multiple sclerosis, type 1 diabetes, arthritis, Tonic spondylitis, rheumatoid arthritis, irritable bowel syndrome, inflammatory bowel disease, chronic enteritis, Alzheimer's disease, polysclerosis, idiopathic pulmonary fibrosis, leprosy and / or chronic fatigue syndrome,
(ii) The subject is a human, domestic animal, laboratory animal, or domestic animal, and / or
(iii) The method comprises administering to the subject an additional therapeutic agent having activity against MAP or an additional therapeutic agent used in the treatment of a condition associated with a MAP infection.
The composition according to any one of claims 1 to 7 .
(ii) 配列番号6、11～20、52、58、60、61、83、及び146のいずれか1つに示されるアミノ酸配列を含む、
請求項9に記載のペプチド。 (i) further comprising the amino acid sequence set forth in SEQ ID NO: 7 or 8 and / or the amino acid sequence set forth in SEQ ID NO: 9 or 10 and / or
(ii) Containing the amino acid sequence set forth in any one of SEQ ID NOs: 6, 11-20, 52, 58, 60, 61, 83, and 146,
The peptide according to claim 9 .
(a) 配列番号22の配列、配列番号22の全長にわたって配列番号22と70%を超えるアミノ酸配列同一性を有するその変異体、又はエピトープを含む配列番号22の少なくとも8個のアミノ酸の断片を含む、ahpCポリペプチド;
(b) 配列番号24の配列、配列番号24の全長にわたって配列番号24と70%を超えるアミノ酸配列同一性を有するその変異体、又はエピトープを含む配列番号24の少なくとも8個のアミノ酸の断片を含む、gsdポリペプチド;
(c) 配列番号26の配列、配列番号26の全長にわたって配列番号26と70%を超えるアミノ酸配列同一性を有するその変異体、又はエピトープを含む配列番号26の少なくとも8個のアミノ酸の断片を含む、p12ポリペプチド、及び/又は
(d) 配列番号30の配列、配列番号30の全長にわたって配列番号30と70%を超えるアミノ酸配列同一性を有するその変異体、又はエピトープを含む配列番号30の少なくとも8個のアミノ酸の断片を含む、mpaポリペプチド
を含む、ポリペプチド。 The amino acid sequence shown in SEQ ID NO: 3 or 5 , as well as
(a) Containing at least eight amino acid fragments of SEQ ID NO: 22 containing the sequence of SEQ ID NO: 22, a variant thereof having more than 70% amino acid sequence identity with SEQ ID NO: 22 over the entire length of SEQ ID NO: 22, or an epitope. , AhpC polypeptide ;
(b) Containing at least eight amino acid fragments of SEQ ID NO: 24 containing the sequence of SEQ ID NO: 24, its variants having more than 70% amino acid sequence identity with SEQ ID NO: 24 over the entire length of SEQ ID NO: 24, or epitopes. , Gsd polypeptide ;
(c) Containing at least eight amino acid fragments of SEQ ID NO: 26 containing the sequence of SEQ ID NO: 26, its variants having more than 70% amino acid sequence identity with SEQ ID NO: 26 over the entire length of SEQ ID NO: 26, or epitopes. , P12 polypeptide, and / or
(d) Containing at least eight amino acid fragments of SEQ ID NO: 30, including the sequence of SEQ ID NO: 30, a variant thereof having more than 70% amino acid sequence identity with SEQ ID NO: 30 over the entire length of SEQ ID NO: 30, or an epitope. , Polypeptides, including mpa polypeptides.
前記gsdポリペプチドが、配列番号34に示すアミノ酸配列をする、
前記p12ポリペプチドが、配列番号36に示すアミノ酸配列を有する、及び/又は
前記mpaポリペプチドが、配列番号40に示すアミノ酸配列を有する；
(ii) ポリペプチドが、
配列番号41に示すアミノ酸配列であって、但し配列番号3に示すアミノ酸配列を含むペプチドがN末端に付加されている、若しくは7位と8位、199位と200位、442位と443位、577位と578位、及び/若しくは820位と821位の間に挿入されている、アミノ酸配列；又は
配列番号42に示すアミノ酸配列であって、但し配列番号3に示すアミノ酸配列を含むペプチドがN末端に付加されている、若しくは7位と8位、199位と200位、442位と443位、582位と583位、及び/若しくは825位と826位の間に挿入されている、アミノ酸配列
を含む；
(iii) ポリペプチドが、配列番号62、63、64、65、67、68及び69のいずれか1つに示すアミノ酸配列を含む；及び／又は
(iv) 配列番号3に示すアミノ酸配列を含むペプチドが、
(a) 配列番号7若しくは8に示すアミノ酸配列、及び／若しくは配列番号9若しくは10に示すアミノ酸配列をさらに含む；及び／若しくは
(b) 配列番号4、6、11～20、52、58、60、61、83、及び146のいずれか1つに示されるアミノ酸配列を含む、
請求項11に記載のポリペプチド。 (i) The ahpC polypeptide has the amino acid sequence set forth in SEQ ID NO: 32.
The gsd polypeptide has the amino acid sequence shown in SEQ ID NO: 34 .
The p12 polypeptide has the amino acid sequence set forth in SEQ ID NO: 36 and / or
The mpa polypeptide has the amino acid sequence set forth in SEQ ID NO: 40 ;
(ii) The polypeptide is
The amino acid sequence shown in SEQ ID NO: 41, except that the peptide containing the amino acid sequence shown in SEQ ID NO: 3 is added to the N-terminal, or positions 7 and 8, 199 and 200, 442 and 443, Amino acid sequences inserted between positions 577 and 578 and / or positions 820 and 821; or
The amino acid sequence shown in SEQ ID NO: 42, except that the peptide containing the amino acid sequence shown in SEQ ID NO: 3 is added to the N-terminus, or at positions 7 and 8, 199 and 200, 442 and 443, Amino acid sequence inserted between positions 582 and 583 and / or positions 825 and 826
including;
(iii) The polypeptide comprises the amino acid sequence set forth in any one of SEQ ID NOs: 62, 63, 64, 65, 67, 68 and 69; and / or
(iv) The peptide containing the amino acid sequence shown in SEQ ID NO: 3 is
(a) further comprises the amino acid sequence set forth in SEQ ID NO: 7 or 8 and / or the amino acid sequence set forth in SEQ ID NO: 9 or 10; and / or
(b) Containing the amino acid sequence set forth in any one of SEQ ID NOs: 4, 6, 11-20, 52, 58, 60, 61, 83, and 146.
The polypeptide according to claim 11 .
(ii) ベクターがウイルスベクターである；及び／又は
(iii) ベクターが、アデノウイルスベクター又はポックスウイルスベクターである、
請求項14に記載のベクター。 (i) The polynucleotide encodes a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 3 , or is the polynucleotide according to claim 13 .
(ii) The vector is a viral vector; and / or
(iii) The vector is an adenovirus vector or a poxvirus vector,
The vector according to claim 14 .
(i)配列番号2に示すMAP P900の領域由来の少なくとも9個の連続するアミノ酸のアミノ酸配列を含むポリペプチド、若しくは前記ポリペプチドをコードするポリヌクレオチド、配列番号3に示すアミノ酸配列からなるペプチド、請求項9若しくは10に記載のペプチド、請求項11若しくは12に記載のポリペプチド、請求項13に記載のポリヌクレオチド、又は請求項14若しくは15に記載のベクターのうちの少なくとも1つ、及び
(ii)同時、逐次、又は個別使用のための有効成分としての少なくとも1つの他の治療剤
を含む、キット。 A kit for treating or preventing MAP infections or conditions or symptoms associated with MAP infections.
(i) A polypeptide containing an amino acid sequence of at least 9 consecutive amino acids derived from the region of MAP P900 shown in SEQ ID NO: 2, a polynucleotide encoding the polypeptide, and an amino acid sequence shown in SEQ ID NO: 3. At least one of a peptide, a peptide according to claim 9 or 10 , a polypeptide according to claim 11 or 12 , a polynucleotide according to claim 13 , or a vector according to claim 14 or 15 . as well as
(ii) A kit comprising at least one other therapeutic agent as an active ingredient for simultaneous, sequential or individual use.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1811382.9A GB201811382D0 (en) | 2018-07-11 | 2018-07-11 | Vaccine |
| GB1811382.9 | 2018-07-11 | ||
| PCT/GB2019/051933 WO2020012177A1 (en) | 2018-07-11 | 2019-07-10 | Immunogenic composition for paratuberculosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021524485A JP2021524485A (en) | 2021-09-13 |
| JPWO2020012177A5 true JPWO2020012177A5 (en) | 2022-07-12 |
Family
ID=63273113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500530A Pending JP2021524485A (en) | 2018-07-11 | 2019-07-10 | Immunogenic composition for paratuberculosis |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210338791A1 (en) |
| EP (1) | EP3820507A1 (en) |
| JP (1) | JP2021524485A (en) |
| KR (1) | KR20210033490A (en) |
| CN (1) | CN113329765A (en) |
| AU (1) | AU2019301899A1 (en) |
| BR (1) | BR112021000312A2 (en) |
| CA (1) | CA3105763A1 (en) |
| GB (1) | GB201811382D0 (en) |
| IL (1) | IL280070B2 (en) |
| MA (1) | MA53131A (en) |
| MX (1) | MX2020013924A (en) |
| SG (1) | SG11202100120TA (en) |
| WO (1) | WO2020012177A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201700487D0 (en) * | 2017-01-11 | 2017-02-22 | Hermon-Taylor John | Diagnostic |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| WO1990011092A1 (en) | 1989-03-21 | 1990-10-04 | Vical, Inc. | Expression of exogenous polynucleotide sequences in a vertebrate |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| EP0632722A4 (en) | 1992-03-20 | 1997-07-30 | Baylor College Medicine | A dna transporter system and method of use. |
| WO1993019768A1 (en) | 1992-04-03 | 1993-10-14 | The Regents Of The University Of California | Self-assembling polynucleotide delivery system |
| US5651981A (en) | 1994-03-29 | 1997-07-29 | Northwestern University | Cationic phospholipids for transfection |
| US5527928A (en) | 1994-09-30 | 1996-06-18 | Nantz; Michael H. | Cationic transport reagents |
| US7074559B2 (en) * | 2002-03-06 | 2006-07-11 | Refents of the University of Minnesota | Mycobacterial diagnostics |
| JP5244593B2 (en) | 2005-08-09 | 2013-07-24 | ハブ バクシーンズ リミテッド | Immunogenic construct |
| EP2948173A1 (en) * | 2013-01-28 | 2015-12-02 | Danmarks Tekniske Universitet | A single or multistage mycobacterium avium subsp. paratuberculosis subunit vaccine |
| GB201700487D0 (en) | 2017-01-11 | 2017-02-22 | Hermon-Taylor John | Diagnostic |
-
2018
- 2018-07-11 GB GBGB1811382.9A patent/GB201811382D0/en not_active Ceased
-
2019
- 2019-07-10 IL IL280070A patent/IL280070B2/en unknown
- 2019-07-10 SG SG11202100120TA patent/SG11202100120TA/en unknown
- 2019-07-10 MA MA053131A patent/MA53131A/en unknown
- 2019-07-10 CA CA3105763A patent/CA3105763A1/en active Pending
- 2019-07-10 EP EP19752222.0A patent/EP3820507A1/en active Pending
- 2019-07-10 JP JP2021500530A patent/JP2021524485A/en active Pending
- 2019-07-10 KR KR1020217004231A patent/KR20210033490A/en unknown
- 2019-07-10 AU AU2019301899A patent/AU2019301899A1/en active Pending
- 2019-07-10 BR BR112021000312-6A patent/BR112021000312A2/en unknown
- 2019-07-10 MX MX2020013924A patent/MX2020013924A/en unknown
- 2019-07-10 WO PCT/GB2019/051933 patent/WO2020012177A1/en unknown
- 2019-07-10 US US17/259,075 patent/US20210338791A1/en active Pending
- 2019-07-10 CN CN201980059761.5A patent/CN113329765A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Miura et al. | Molecular cloning of nucleobindin, a novel DNA-binding protein that contains both a signal peptide and a leucine zipper structure | |
| JP5254792B2 (en) | Treatment for myasthenia gravis | |
| JP5557528B2 (en) | Treatment method for peripheral neuropathy | |
| JP2005515771A5 (en) | ||
| JP2006525330A5 (en) | ||
| JP2008538183A5 (en) | ||
| JP2009525757A5 (en) | ||
| Franchini et al. | Cloning and purification of the rainbow trout fifth component of complement (C5) | |
| JP2002502600A (en) | Human serine protease and serpin polypeptide | |
| JP2006502702A5 (en) | ||
| Hedstrom et al. | A malaria sporozoite surface antigen distinct from the circumsporozoite protein. | |
| JP2021525281A (en) | Use of RyR2 protein or RyR2 recombinant protein in the manufacture of anti-heart failure drugs | |
| CZ2003947A3 (en) | Shortened and mutated human chemokine | |
| JPWO2020012177A5 (en) | ||
| US7531177B2 (en) | Surface protein of leptospira | |
| JP2005512518A5 (en) | ||
| US5856305A (en) | Peptides endowed with antiinflammatory activity | |
| JP2009504149A5 (en) | ||
| WO2016109823A1 (en) | Treatment of pediatric growth hormone deficiency with human growth hormone analogues | |
| MXPA00009899A (en) | A polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof. | |
| JP2004535161A5 (en) | ||
| JP2005524387A5 (en) | ||
| JP5795079B2 (en) | Antimicrobial peptide polypolymer complex expressed on the cell surface | |
| WO1998038312A1 (en) | Bacterial elastin binding protein, nucleic acid sequence encoding same and diagnostic and therapeutic methods of use thereof | |
| CN111825760B (en) | Polypeptide and application thereof in resisting glomerular basement membrane disease |